potential mechanisms
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity
Emerging research is also investigating the broader systemic effects of GLP-1, GIP, and glucagon receptor agonists, including potential roles in: Metabolic dysfunction research Cardiometabolic health Inflammatory-response pathways Cellular stress and oxidative-stress pathways Neuroprotective and systemic health research Responses and tolerability may vary significantly between individuals depending on dosage, consistency, nutrition, lifestyle, stress, sleep, hormonal balance, and overall metabolic health
marketed as Mounjaro for T2DM and Zepbound for obesity), is a 39-amino acid peptide acylated with a C20:0 fatty diacid moiety to lysine residue at position 20 with a molecular weight of 4.8 kDa [ Figure 2 , Table 1 ]
Common causes include not enough protein, too little overall intake causing your body to downshift its metabolism, dehydration or constipation masking fat loss on the scale, and no strength training causing lean mass to drop faster
Regular meals help stabilize energy and digestion, which are both crucial when healing
